T1	Negation 29 41	discontinued
T2	Multiplier 17 28	permanently
R1	Has_multiplier Arg1:T1 Arg2:T2	
T3	Drug 47 56	nilotinib
T4	Procedure 57 66	treatment
R2	AND Arg1:T4 Arg2:T3	
R3	Has_negation Arg1:T4 Arg2:T1	
T5	Condition 94 115	unacceptable toxicity
T6	Observation 117 131	non-compliance
T7	Procedure 135 151	study procedures
R4	AND Arg1:T6 Arg2:T7	
T8	Negation 153 163	withdrawal
T9	Observation 167 174	consent
R5	Has_negation Arg1:T9 Arg2:T8	
T10	Observation 178 194	any other reason
*	OR T9 T10 T5 T6
T11	Scope 94 194	unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason
R6	Has_scope Arg1:T4 Arg2:T11	
T12	Qualifier 225 243	Novartis sponsored
T13	Observation 207 224;244 261	participated in a combination trial
T14	Non-representable 195 387	Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy
T15	Procedure 425 434	treatment
T16	Temporal 405 414	currently
R7	Has_temporal Arg1:T15 Arg2:T16	
T17	Drug 440 455	any medications
T18	Qualifier 461 506	have the potential to prolong the QT interval
T19	Qualifier 510 537	inducing Torsade de Pointes
*	OR T18 T19
T20	Scope 461 537	have the potential to prolong the QT interval or inducing Torsade de Pointes
R8	Has_scope Arg1:T17 Arg2:T20	
R9	AND Arg1:T15 Arg2:T17	
T21	Non-representable 542 749	the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study
T22	Observation 750 758	Pregnant
T23	Observation 762 769	nursing
T24	Person 782 787	women
*	OR T23 T22
T25	Observation 771 780	lactating
R10	Subsumes Arg1:T23 Arg2:T25	
T26	Observation 922 941	hcG laboratory test
T27	Value 913 921	positive
R11	Has_value Arg1:T26 Arg2:T27	
R12	Has_context Arg1:T22 Arg2:T26	
T28	Person 943 948	Women
T29	Observation 952 975	child-bearing potential
T30	Observation 998 1042	physiologically capable of becoming pregnant
T31	Person 992 997	women
T32	Negation 1044 1050	unless
T33	Qualifier 1066 1090	highly effective methods
T34	Observation 1094 1107	contraception
T35	Temporal 1108 1124	during the study
T36	Temporal 1129 1174	for 30 days after the final dose of nilotinib
T37	Reference_point 1147 1174	the final dose of nilotinib
R13	Has_index Arg1:T36 Arg2:T37	
T38	Scope 1108 1174	during the study and for 30 days after the final dose of nilotinib
R14	Has_scope Arg1:T34 Arg2:T38	
R15	Has_qualifier Arg1:T34 Arg2:T33	
R16	Has_negation Arg1:T34 Arg2:T32	
T39	Scope 992 1174	women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib
T40	Scope 943 975	Women of child-bearing potential
R17	Subsumes Arg1:T40 Arg2:T39	
